🚨 Promising data from Cayuga Biotech on CAY001, a first-in-class polyphosphate-based therapy, were presented at #ACC2025. CAY001 demonstrated a 36% increase in survival and 59% improvement in bleeding time in preclinical models of P2Y12 inhibitor-treated bleeding. With over 4 million Americans on P2Y12 inhibitors, excessive bleeding remains a major clinical challenge. Charles V Pollack, MD highlights the significance: "These early data are promising as they demonstrate CAY001’s ability to bypass P2Y12 inhibition to activate platelets via thrombin and restore the normal clotting response." As an inert injectable that selectively accelerates clotting at bleeding sites, CAY001 represents a potential breakthrough in managing hemorrhage risk for patients on blood thinners. Exciting progress from Cayuga Biotech—looking forward to next steps in development! 🔬💉 #BackedbySOSV #SOSV #IndieBio SOSV Cayuga Biotech Andrea Ashford-Hicks Damien Kudela
At the American College of Cardiology (ACC) Meeting, Cayuga presented data demonstrating that CAY001 significantly improved survival and bleeding outcomes in animals treated with a P2Y12 inhibitor of platelet function. Hemorrhage in patients on platelet inhibitors, such as Plavix, can be life-threatening. The Cayuga team is proud to be sharing this data on our first-in-class investigational drug. ACC Poster Presentation Details: Title: A Novel Synthetic Short-chain Polyphosphate (polyP) Complexed with Silica Nanoparticle (SNP) Bypasses Cangrelor-induced P2Y12 Inhibition and Reduces Blood Loss in a Rat Tail Transection Model Publication Number: Board 45 Session Name: 1105: Featured Fields 05 #Hemorrhage #PlateletInhibitors #Plavix #P2Y12 #platelet